Decreased enzymatic activity of 5,10-methylene tetrahydrofolate reductase affects the development of several diseases

  • Maša Vidmar Univerzitetni klinični center Ljubljana Ginekološka klinika
  • Jasna Grželj KRKA, d.d. Novo mesto Šmarješka 6 Novo mesto
  • Ksenija Gersak Univerza v Ljubjani Medicinska fakulteta in Univerzitetni klinični center Ljubljana Ginekološka klinika
  • Irena Mlinarič-Raščan Univerza v Ljubljani Fakulteta za farmacijo Aškerčeva 7 Ljubljana
Keywords: folic acid, MTHFR polymorphisms, folate metabolism, disease risk, drug interaction

Abstract

The importance of folates in human physiology is well known, as are various pathologies associated with low folate status. Folate deficiency can occur due to low dietary intake, genetic predisposition or treatment with medicines affecting the folate status. The aim of this paper is to explore the importance of determining genetic polymorphisms which influence the levels of biologically active folate. MTHFR is involved in the transformation of 5,10-methylene-THF to 5-methyl-THF. Polymorphisms of the MTHRF gene are associated with decreased enzymatic activity.

Only 9.3 % of the population in Slovenia displays full activity of the MTHFR enzyme; these subjects are non-mutated homozygotes (wild-type alleles). In contrast, the average enzymatic activity in subjects with mutated alleles is between 50 and 60 %. MTHFR polymorphism is associated with an increased risk of hyperhomocysteinemia and cardiovascular diseases, neurological disorders and various types of cancer. There is also an increased risk for congenital malformations. Folic acid food fortification was introduced in some countries in order to assure an adequate folate status in the population. However, this approach does not address the decreased activity of MTHFR.

Polymorphism in the key enzymes of the folate cycle is common. Determination of the genetic predisposition is therefore plausible in the most vulnerable groups of the population, such as pregnant women and patients receiving medicines influencing the folate cycle in various ways, e.g. 5-fluorouracil, methotrexate and 6-mercaptopurine. Genotyping would allow the identification of patients at high risk for suboptimal folate status.

Downloads

Download data is not yet available.

References

Duan S, Huang RS, Zhang W, Mi S, Bleibel WK, Kistner EO, Cox NJ, Dolan ME. Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics. 2009;10(4):549–63.

Mahmood L. The metabolic processes of folic acid and Vitamin B12 deficiency. J Health Res Rev. 2014;1:5-9.

European Food Safety Authority (EFSA). Scientific Opinion on the evaluation of allergenic foods and food ingredients for labelling purposes. EFSA J. 2014;12:1-277.

National Institutes of Health (NIH). Folate - Dietary Supplement Fact Sheet. NIH [Internet] 2016. Citirano:28.1.2016. Dostopno na:https://ods.od.nih.gov/factsheets/Folate-HealthProfessional.

Worthington P, Schechter L. Drug-Nutrient Interactions Involving Folate. In: Boullata JI, Armenti VT, Handbook of Drug-Nutrient Interactions. 2nd edition. USA. 2010;513-37.

Imbard A., Benoist J.-F., Blom H. Neural Tube Defects, Folic Acid and Methylation. Int. J. Environ. Res. Public Health. 2013;10:4352-89.

Blom HJ. Folic acid, methylation and neural tube closure in humans. Birth Defects Res A Clin Mol Teratol. 2009;85(4):295-302.

Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 2011;34:75–81.

Nazki FH, Sameer AS, Ganaie BA. Folate: Metabolism, genes, polymorphisms and the associated diseases.Gene. 2014;533:11-20.

Bailey LB, Gregory JF. Recent Advances in Nutritional Science Folate Metabolism and Requirements. J. Nutr. 1999;129:779-82.

Zetterberg H, Regland B, Palmér M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur. J. Hum. Genet. 2002;10:113-8.

Sharp L, Little J. Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review. Am J Epidemiol. 2004;159:423–43.

Bohanec P, Dolžan V. Genetski polimorfizmi encimov v presnovni poti folata v zdravi slovenski populaciji. Zdrav Vestn. 2004;73:807-13.

Kniffin CL. 5, 10-methylenetetrahydrofolate reductase, MTHFR. OMIM Entry [Internet] 2015. Citirano:25.3.2016. Dostopno na:http://www.omim.org/entry/607093.

Garilli B. MTHFR Mutation: A Missing Piece in the Chronic Disease Puzzle. ND, Contrib. Writ. 2012; 13(2).

Jacques PF, Bostom AG, Williams RR, Ellison C, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7–9.

Crider KS, Zhu J-H, Hao L, Yang Q-H, Yang TP, Gindler J, Maneval DR, Quinlivan EP, Li Z, Bailey LB, Berry RJ. MTHFR 677C→T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr. 2011;93(6):1365-72.

Johansson M, Van Guelpen B, Hultdin J, Wiklund J, Wiklund F, Adami H-O, Bälter K, Grönberg H, Stattin P. The MTHFR 677C→T polymorphism and risk of prostate cancer: results from the CAPS study. Cancer Causes and Control. 2007;18(10):1169-74.

Czeizel A, Dudás I, Vereczkey A, Bánhidy F. Folate Deficiency and Folic Acid Supplementation: The Prevention of Neural-Tube Defects and Congenital Heart Defects. Nutrients. 2013;5:4760–75.

Guéant-Rodriguez R-M, Guéant J-L, Debard R, Thirion S, Hong LX, Bronowicki J-P, Namour F, Chabi NW, Sanni A, Anello G, Bosco P, Romano C, Amouzou E, Arrieta HR, Sánchez BE, Romano A, Herbeth B, Guilland J-C, Mutchinick OM. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comperative study in Mexican, West African, and European populations. Am J Clin Nutr. 2006;83(3):701-7.

Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation. 2015;132:6–9.

Leclerc D, Sibani S, Rozen R. Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations/Polymorphisms. Madame Curie Bioscience Database [Internet]. Citirano:16.11.2015. Dostopno na:http://www.ncbi.nlm.nih.gov/books/NBK6561.

Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, López MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martínez-Frías ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003;40:619-25.

Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res. 2009;33:1344-8.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–172.

Kennedy DA, Stern SJ, Matok I, Moretti ME, Sarkar M, Adams-Webber T, Koren G. Folate Intake, MTHFR Polymorphisms, and the Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer Epidemiol. 2012;1-24.

DNA - Gen za MTHFR, polimorfizem 1298 A>C. Univerza v Ljubljani, Fakulteta za farmacijo [Internet]. Citirano:15.12.2015. Dostopno na:http://www.ffa.uni-lj.si/raziskave/laboratorij-za-molekularno-diagnostiko/seznam-laboratorijskih-preiskav-in-storitev/mthfr-1298-ac.

Zappacosta B, Romano L, Persichilli S, Cutrone LA, Graziano M, Vitrani A, Di Castelnuovo A, Giardina B, Musumeci S, Mastroiacovo P. Genotype Prevalence and Allele Frequencies of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) C677T and A1298C Polymorphisms in Italian Newborns. Lab. Med. 2009;40(12):732-6.

Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J. Hum. Genet. 2003;48:1-7

I Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: An Examination of C677T and A1298C mutations. Am. J. Hum. Genet. 200;67:986-90.

Brown NM, Pratt VM, Buller A, Pike-Buchanan L, Redman JB, Sun W, Chen R, Crossley B, McGinniss MJ, Quan F, Strom CM. Detection of 677CT/1298AC "double variant" chromosomes: Implications for interpretation of MTHFR genotyping results. Genet. Med. 2005;7:278-82.

Društvo za zdravje srca in ožilja Slovenije. Smernice za družine z otrokom s prirojeno srčno napako. Ljubljana; 2011.

Xuan C, Li H, Zhao J-X, Wang H-W, Wang Y, Ning C-P, Liu Z, Zhang B-B, He G-W, Lun L-M. Association Between MTHFR Polymorphisms and Congenital Heart Disease: A Meta-analysis based on 9,329 cases and 15,076 controls. Sci. Rep. 2014;4(7311):1-13

Nie Y, Gu H, Gong J,Wang J, Gong D, Cong X, Chen X, Hu S. Methylenetetrahydrofolate reductase C677T polymorphism and congenital heart disease: a meta-analysis. Clin. Chem. Lab. Med. 2011;49(12):2101-8.

Hobbs CA, James SJ, Parsian A, Krakowiak PA, Jernigan S, Greenhaw JJ, Lu Y, Cleves MA. Congenital heart defects and genetic variants in the methylenetetrahydroflate reductase gene. J. Med. Genet. 2006;43:162-6.

Alfarra HY, Alfarra SR, Sadiq MF. Neural tube defects between folate metabolism and genetics. Indian. J. Hum. Genet. 2011;17(3):126-31.

Greene NDE, Stanier P, Copp AJ. Genetics of human neural tube defects. Hum. Mol.

Genet. 2009;18(2):113-29.

Czeizel AE, Dudás I, Paput L, Bánhidy F. Prevention of neural-tube defects with periconceptional folic acid, methylfolate, or multivitamins? Ann. Nutr. Metab. 2011;58(4):263–71.

Wang XW, Luo YL, Wang W, Zhang Y, Chen Q, Cheng YL. Association between MTHFR A1298C polymorphism and neural tube defect susceptibility: A metaanalysis. Am. J. Obstet. Gynecol. 2012;206(3):251.e1–251.e7.

Brito LA, Meira JG, Kobayashi GS, Passos-Bueno MR. Genetics and Management of the Patient with Orofacial Cleft. Plast. Surg. Int. 2012;1-11.

Luo YL, Cheng YL, Ye P, Wang W, Gao XH, Chen Q. Association between MTHFR polymorphisms and orofacial clefts risk: A meta-analysis. Birth Defects Res. A Clin. Mol. Teratol. 2012;94(4):237-44.

Karas-Kuželički N, Šmid A, Kek T, Eberlinc A, Geršak K, Mlinarič-Raščan I. Korelacija genotipov s pojavnostjo OFC. (preliminarni rezultati).

Varga EA, Sturm AC, Misita CP, Moll S. Homocysteine and MTHFR Mutations: Relation to Thrombosis and Coronary Artery Disease. Circulation. 2005:111:289–293.

Phillips T. The Role of Methylation in Gene Expression. Nat. Educ. 2008;1(1):116.

Pooja S, Carlus J, Sekhar D, Francis A, Gupta N, Konwar R, Kumar S, Kumar S, Thangaraj K, Rajender S. MTHFR 677C>T Polymorphism and the Risk of Breast Cancer: Evidence from an Original Study and Pooled Data for 28031 Cases and 31880 Controls. PLoS One. 2015;13(3):e0120654.

Lu C, Xie H, Wang F, Shen H, Wang J. Diet folate, DNA methylation and genetic polymorphisms of MTHFR C677T in association with the prognosis of esophageal squamous cell carcinoma. BMC Cancer. 2011;11:91.

Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day INM, Ebrahim.The thermolabile variant of MTHFR is associated with depression in the British Women’s Heart and Health Study and a meta-analysis. Mol. Psychiatry. 2006;11:352–60.

Morrissette DA. Second messenger psychiatric disorders: a messed up MTHFR.(methylenetetrahydrofolate reductase)(Report)[Internet] 2011. Citirano:20.1.2016. Dostopno na:http://www.highbeam.com/doc/1G1-252496863.html.

Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern. Med. Rev. 2008;13(3):216-26.

Crider KS, Bailey LB, Berry RJ. Folic Acid Food Fortification—Its History, Effect, Concerns, and Future Directions. Nutrients. 2011;3(3):370–84.

Centers for Disease Control and Prevention (CDC). Spina Bifida and Anencephaly Before and After Folice Acid Mandate - United States, 1995-1996 and 1999-2000. MMWR

Morb. Mortal. Wkly. Rep. 2004;57(17):362-5.

Food Fortification Initiative, Enhancing Grains for Healthier Lives. Europe [Internet]. Citirano: 25.11.2015. Dostopno na:http://www.ffinetwork.org/regional_activity/europe.php.

Farkaš J. Javnozdravstveni vidiki dodajanja folne kisline živilom [Seminar]. Ljubljana: Katedra za javno zdravje, Socialna medicina. 2008.

Soediono B. Folacin. J. Chem. Inf. Model. 1989;53:160.

Femibion - Pre-conception + Pregnancy. Leaflet

SPC, Labeling and Package Leaflet. Folic Acid - Tifol. 2010;3-7.

Seremak-Mrozikiewicz A. Metafolin - alternative for folate deficiency supplementation in pregnant women. Ginekol. Pol. 2013;84(7):641-6.

Gene: MTHFR. PharmGKB [Internet]. Citirano: 25.3.2016. Dostopno na: https://www.pharmgkb.org/gene/PA245#tabview=tab0&subtab=33.

JAZMP-IB. Povzetek glavnih značilnosti zdravila – Metotreksat Actavis. 2015.

Van Gelder MM, van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N. Tetatogenic mechanisms of medical drugs. Hum. Reprod. Update. 2010;16(4):378-94.

Karas-Kuzelicki N, Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics. 2009;10(8):1309-22.

De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer. 2009;45(8):1333-51.

Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sørensen JB, Andersen PK, Poulsen HE. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol. 2009;20(10):1660-6.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol. 2010;69(1):58-66.

Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate Reductase Polymorphism in Advanced Colorectal Cancer : A Novel Genomic Predictor of Clinical Response to Fluoropyrimidine-based Chemotherapy. Clin. Cancer Res. 2003;9:1611-5.

Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol. 2006;13(11):1379-85.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J. Clin. Oncol. 2007;25(10):1247-54.

Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CL, Li S, Liu H, Farin FM, Potter JD. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98(1):231-5.

Świerkot J, Ślęzak R, Karpiński P, Pawłowska J, Noga L, Szechiński J, Wiland P. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol. Arch. Med. Ween. 2015;125(3):152–60.

Yang L, Xin H, Luhang X. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 2012;33(5):1445-54.

Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sorà F, Mele L, Annino L, Leone G, Sica S. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 2002;13(12):1915-8.

Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia. 2009;23:971-4.

JAZMP-R/001. Povzetek glavnih značilnosti zdravila –PURI-NETHOL. 2013.

Moon W, Loftus Jr. EV. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2016;43:863-83.

Health Canada Santé Canada (HCSC) label information for ethinyl estradiol, norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1. PharmGKB [Internet]. Citirano:2.4.2016. Dostopno na: https://www.pharmgkb.org/label/PA166127695?previousQuery=mthfr.

Laboratorij za molekularno genetiko. Univerza v Ljubljani, Fakulteta za farmacijo [Internet]. Citirano: 20.3.2016. Dostopno na:http://www.ffa.uni-lj.si/raziskave/laboratorij-za-molekularno-diagnostiko.

Panovska Z. Povezanost polimorfizmov v izbranih genih folatnega cikla z napakami nevralne cevi [Diplomska naloga]. Ljubljana: Fakulteta za farmacijo;2010.

Published
2016-07-26
How to Cite
1.
Vidmar M, Grželj J, Gersak K, Mlinarič-Raščan I. Decreased enzymatic activity of 5,10-methylene tetrahydrofolate reductase affects the development of several diseases. ZdravVestn [Internet]. 26Jul.2016 [cited 17Sep.2019];85(5-6). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/1554
Section
Professional Article